Immunologic Approaches to Acute Leukemia in the Elderly

Sherif Farag, Michael A. Caligiuri

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The outcome of older patients with acute leukemia remains poor with few long-term survivors, indicating the need for treatment approaches that target pro-apoptotic pathways not influenced by chemotherapy resistance. For a long time, natural killer (NK) cells have held promise for cancer immunotherapy because, unlike T lymphocytes, they can kill tumor cells without the need for tumor-specific antigen recognition. In the treatment of acute leukemia, NK cell-based therapies have focused on in vivo expansion and activation with cytokines with only modest success. However, recent understanding of the importance of NK receptors for the recognition and lysis of leukemia cells suggests novel therapeutic strategies. The balance of inhibitory and activating signals through surface receptors, recognizing major histocompatibility complex (MHC) class I and class I-like molecules on target cells, determines whether NK cells activate killing. In this review, we discuss the biologic rationale for therapeutic strategies harnessing NK cells and focus on novel directions for their future use in elderly patients with acute leukemia.

Original languageEnglish (US)
Pages (from-to)118-125
Number of pages8
JournalSeminars in Hematology
Volume43
Issue number2
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Natural Killer Cells
Leukemia
Neoplasm Antigens
Therapeutics
Cell- and Tissue-Based Therapy
Major Histocompatibility Complex
Immunotherapy
Survivors
Neoplasms
Cytokines
T-Lymphocytes
Drug Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Immunologic Approaches to Acute Leukemia in the Elderly. / Farag, Sherif; Caligiuri, Michael A.

In: Seminars in Hematology, Vol. 43, No. 2, 04.2006, p. 118-125.

Research output: Contribution to journalArticle

Farag, Sherif ; Caligiuri, Michael A. / Immunologic Approaches to Acute Leukemia in the Elderly. In: Seminars in Hematology. 2006 ; Vol. 43, No. 2. pp. 118-125.
@article{348e375a051e48bfb29db7d08b6e6a1e,
title = "Immunologic Approaches to Acute Leukemia in the Elderly",
abstract = "The outcome of older patients with acute leukemia remains poor with few long-term survivors, indicating the need for treatment approaches that target pro-apoptotic pathways not influenced by chemotherapy resistance. For a long time, natural killer (NK) cells have held promise for cancer immunotherapy because, unlike T lymphocytes, they can kill tumor cells without the need for tumor-specific antigen recognition. In the treatment of acute leukemia, NK cell-based therapies have focused on in vivo expansion and activation with cytokines with only modest success. However, recent understanding of the importance of NK receptors for the recognition and lysis of leukemia cells suggests novel therapeutic strategies. The balance of inhibitory and activating signals through surface receptors, recognizing major histocompatibility complex (MHC) class I and class I-like molecules on target cells, determines whether NK cells activate killing. In this review, we discuss the biologic rationale for therapeutic strategies harnessing NK cells and focus on novel directions for their future use in elderly patients with acute leukemia.",
author = "Sherif Farag and Caligiuri, {Michael A.}",
year = "2006",
month = "4",
doi = "10.1053/j.seminhematol.2006.01.006",
language = "English (US)",
volume = "43",
pages = "118--125",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Immunologic Approaches to Acute Leukemia in the Elderly

AU - Farag, Sherif

AU - Caligiuri, Michael A.

PY - 2006/4

Y1 - 2006/4

N2 - The outcome of older patients with acute leukemia remains poor with few long-term survivors, indicating the need for treatment approaches that target pro-apoptotic pathways not influenced by chemotherapy resistance. For a long time, natural killer (NK) cells have held promise for cancer immunotherapy because, unlike T lymphocytes, they can kill tumor cells without the need for tumor-specific antigen recognition. In the treatment of acute leukemia, NK cell-based therapies have focused on in vivo expansion and activation with cytokines with only modest success. However, recent understanding of the importance of NK receptors for the recognition and lysis of leukemia cells suggests novel therapeutic strategies. The balance of inhibitory and activating signals through surface receptors, recognizing major histocompatibility complex (MHC) class I and class I-like molecules on target cells, determines whether NK cells activate killing. In this review, we discuss the biologic rationale for therapeutic strategies harnessing NK cells and focus on novel directions for their future use in elderly patients with acute leukemia.

AB - The outcome of older patients with acute leukemia remains poor with few long-term survivors, indicating the need for treatment approaches that target pro-apoptotic pathways not influenced by chemotherapy resistance. For a long time, natural killer (NK) cells have held promise for cancer immunotherapy because, unlike T lymphocytes, they can kill tumor cells without the need for tumor-specific antigen recognition. In the treatment of acute leukemia, NK cell-based therapies have focused on in vivo expansion and activation with cytokines with only modest success. However, recent understanding of the importance of NK receptors for the recognition and lysis of leukemia cells suggests novel therapeutic strategies. The balance of inhibitory and activating signals through surface receptors, recognizing major histocompatibility complex (MHC) class I and class I-like molecules on target cells, determines whether NK cells activate killing. In this review, we discuss the biologic rationale for therapeutic strategies harnessing NK cells and focus on novel directions for their future use in elderly patients with acute leukemia.

UR - http://www.scopus.com/inward/record.url?scp=33646008840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646008840&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2006.01.006

DO - 10.1053/j.seminhematol.2006.01.006

M3 - Article

C2 - 16616045

AN - SCOPUS:33646008840

VL - 43

SP - 118

EP - 125

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 2

ER -